2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文讨论生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal for ImmunoTherapy of Cancer J IMMUNOTHER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
70人评分
我要评分
声誉 9.2 影响力 8.1 速度 7.0 | |||||||||||||||||||||||||||||||||||||
| 期刊ISSN | 2051-1426 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2026年9月20日：7.91 | |||||||||||||||||||||||||||||||||||||
| 2025-2026自引率 | 3.4%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 12.303数据由网友[憧憬奶茶]收集提供 | |||||||||||||||||||||||||||||||||||||
| h-index | 36 | |||||||||||||||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||||||||
| 期刊官方网站 | https://jitc.bmj.com/ | |||||||||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/jitc | |||||||||||||||||||||||||||||||||||||
| 作者指南网址 | https://jitc.bmj.com/pages/authors | |||||||||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer Author: Lu, Shun; Yu, Yan; Zhang, Jun; Wang, Qiming; Cho, Eun Kyung; Zhao, Jun; Kim, Se Hyun; Lee, Youngjoo; Clay, Timothy D.; Yang, Tsung-Ying; Chang, Gee-Chen; Yang, Haiyuan; Zuo, Yunxia; Liu, Rui; Sun, Pu; Kim, Hye Ryun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015474 SPP1+ macrophage-induced CD74+ tumor cells promote adrenocortical carcinoma tumor thrombus via the SPP1/CD44/JAK/STAT signaling Author: Zhang, Houliang; Xu, Kangjie; Zhen, Lan; Jiang, Yanji; Chou, Anyang; Chen, Ming; Chen, Yu; Wu, Jianping; Mao, Weipu Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015080 Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses Author: Ma, Jie-Tao; Sun, Li; Zhang, Ling-Yun; Huang, Le-Tian; Zhang, Shu-Ling; Sun, Nan; Dong, Yu-Yang; Li, Xiao-Han; Yue, Yong; Yang, Mei-Qi; Jiang, Jia-Yuan; Feng, Jin; Han, Xue; Wu, Yu-Ting; Wang, Shi-Wei; Jiang, Yu-Ting; Guan, Shi-Tong; Chen, Xue-Mei; Han, Cheng-Bo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-016280 NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma Author: Li, Yan; Zhuang, Xiaomei; Tang, Yisen; Feng, Wanhua; Huang, Yingzi; Li, Zhu; Lin, Yuanyu; Tang, Di; Deng, Gang; Peng, Songlin; Qin, Wei; Chen, Zubing; Wu, Xiaoying; Song, Ze; Boor, Patrick P. C.; Buschow, Sonja, I; Sprengers, Dave; Zhou, Guoying Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015639 | |||||||||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal for ImmunoTherapy of Cancer的语言要求，还能让Journal for ImmunoTherapy of Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal for ImmunoTherapy of Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢（2篇） 。
提交文稿 | |||||||||||||||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：tumour immunology、cancer immunotherapy、immunotherapy biomarkers 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||||||||
| 通讯方式 | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR | |||||||||||||||||||||||||||||||||||||
| 出版商 | BMJ PUBLISHING GROUP | |||||||||||||||||||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Molecular Medicine | |||||||||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||||||||||
| 出版年份 | 2013 | |||||||||||||||||||||||||||||||||||||
| 年文章数 | 587点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 95.06% | |||||||||||||||||||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | |||||||||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 18 Weeks | |||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal for ImmunoTherapy of Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢（2篇） 。 提交文稿 | |||||||||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer Author: Lu, Shun; Yu, Yan; Zhang, Jun; Wang, Qiming; Cho, Eun Kyung; Zhao, Jun; Kim, Se Hyun; Lee, Youngjoo; Clay, Timothy D.; Yang, Tsung-Ying; Chang, Gee-Chen; Yang, Haiyuan; Zuo, Yunxia; Liu, Rui; Sun, Pu; Kim, Hye Ryun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015474 PubMed DOI |
| 2. | SPP1+ macrophage-induced CD74+ tumor cells promote adrenocortical carcinoma tumor thrombus via the SPP1/CD44/JAK/STAT signaling Author: Zhang, Houliang; Xu, Kangjie; Zhen, Lan; Jiang, Yanji; Chou, Anyang; Chen, Ming; Chen, Yu; Wu, Jianping; Mao, Weipu Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015080 PubMed DOI |
| 3. | Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses Author: Ma, Jie-Tao; Sun, Li; Zhang, Ling-Yun; Huang, Le-Tian; Zhang, Shu-Ling; Sun, Nan; Dong, Yu-Yang; Li, Xiao-Han; Yue, Yong; Yang, Mei-Qi; Jiang, Jia-Yuan; Feng, Jin; Han, Xue; Wu, Yu-Ting; Wang, Shi-Wei; Jiang, Yu-Ting; Guan, Shi-Tong; Chen, Xue-Mei; Han, Cheng-Bo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-016280 PubMed DOI |
| 4. | NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma Author: Li, Yan; Zhuang, Xiaomei; Tang, Yisen; Feng, Wanhua; Huang, Yingzi; Li, Zhu; Lin, Yuanyu; Tang, Di; Deng, Gang; Peng, Songlin; Qin, Wei; Chen, Zubing; Wu, Xiaoying; Song, Ze; Boor, Patrick P. C.; Buschow, Sonja, I; Sprengers, Dave; Zhou, Guoying Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015639 PubMed DOI |
| 5. | CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers Author: Che, Xiumei; Yun, Un-Jung; Lee, Junsub; Koh, Hyun-Hee; Lee, Ju-Yeon; Jeon, Jungmin; So, Subin; Kim, Youngyoub; Chae, Jin-A; Zhang, Xianglan; Kim, Hyoyoung; Hwang, Jiwoo; Park, Eunhyang; Nam, Eun Ji; Kim, Gun Min; Jung, Minkyu Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2025-014131 PubMed DOI |
| 6. | LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma Author: Hou, Xiaoshuang; Lin, Lan; Zhang, Po; Li, Youwei; Dong, Minhai; Chen, Sui; Oyang, Xiaohu; Wang, Jingbo; Cheng, Fangling; Li, Xiaopeng; Zhao, Min; Mao, Feng; Yu, Xingjiang; Hu, Desheng; Wang, Baofeng; Guo, Dongsheng Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015730 PubMed DOI |
| 7. | Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort Author: Yu, Haopeng; Li, Xiaoying; Cheng, Xuan; Deng, Yan; Wang, Yuqi; Li, Yu; Liu, Bingjie; Huang, Zixing; Cao, Dan Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015705 PubMed DOI |
| 8. | Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study Author: Wei, Zhigong; Chen, Huijiao; Wang, Dejuan; Li, Leyu; Pei, Yiyan; Yang, Huaju; Wang, Feng; Jin, Jing; Luo, Yiqiao; Chen, Fei; Liu, Jun; Peng, Xingchen Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2025-014100 PubMed DOI |
| 9. | PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype Author: Wang, Qiyue; Chen, Yinqi; Huang, Dongdong; Wu, Hui; Wu, Tongshuo; Han, Yuejun; Cai, Chengzhi; Li, Jingjie; Shao, Yifei; Ruan, Jian; Jiang, Haiping Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015452 PubMed DOI |
| 10. | Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study Author: Xia, Jin; Meng, Xiangrui; Jiang, Guozhong; Hong, Yonggui; Ji, Yinghua; Wang, Cailing; Yang, Xiuli; Meng, Yu; Zhang, Weijie; Luo, Zhiquan; Cui, Donghai; Wang, Junsheng; Shan, Zhengzheng; Guan, Lulu; Lu, Yao; Yang, Xu; Ren, Chao; Meng, Xiangli; Wang, Hongli; Shen, Ling; Zhang, Yaosheng; Kou, Zongqiang; Lu, Taiying; Fan, Qingxia; Quante, Michael; Zhao, Tongjin; Li, Shenglei; Wang, Feng Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 9, pp. -. DOI: 10.1136/jitc-2026-015887 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共387条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
